More News! 21 Dec 2017 Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […] December 21, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 British Gene Therapy Gets a Huge £85M Boost in Series B Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […] December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2017 British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […] December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2017 Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster? GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018. GW Pharma develops therapies for a range of diseases, including autism, epilepsy and brain cancer using its cannabinoid product platform. In a rundown of the top 10 […] December 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 14 Dec 2017 New Biotech in Oxford Takes on Arthritis of the Spine Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […] December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2017 Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […] December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations? Mereo BioPharma’s drug, BCT-197, more than halved the number of hospitalizations of chronic obstructive pulmonary disease patients during a Phase II trial. Mereo BioPharma develops therapies for patients with rare diseases. Today, it has announced that BCT-197, or acumapimod, improved lung function and reduced the number of hospitalizations for treatment in chronic obstructive pulmonary disease (COPD) patients. One of […] December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 A London Biotech Aims to Overtake the Dry Eye Syndrome Market TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […] December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2017 CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […] December 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 New Gene Therapy for Parkinson’s will be Developed in the UK Synpromics and UCL will collaborate to develop a gene therapy to treat Parkinson’s disease that only targets specific neurons involved in the disease. Synpromics, based in Edinburgh, Scotland, is a company focusing on gene control. The biotech has decided to put its technology to use for the development of a gene therapy for Parkinson’s in […] November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2017 Let’s Clean Up Our Oceans! New Technique Can Find Even the Tiniest Pieces of Plastic Current research suggests that we only remove 1% of the plastic waste in our oceans. Thankfully, researchers in the UK have developed a technique to find the rest! Researchers at the University of Warwick, UK, have developed a new and cheap method to find even the smallest bits of plastic that are floating around in […] November 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2017 British SynBio Startup Lands $3.6M for AI-Driven Protein Engineering LabGenius is using synthetic biology to develop new materials. The funding allows the biotech to set up its own research facility to develop its platform. LabGenius, a new biotech startup based in London, is using artificial intelligence (AI) to drive the development of new materials. This morning, the company has announced that it has received […] November 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email